Clinical Trials Logo
  1. Home
  2. Genital Neoplasms, Male
  3. NCT00210041

Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

Genital Neoplasms, Male Clinical Trial

Official title:
Phase 2 Study for Treatment of Penis Epidermoid Carcinoma Loco-regionally Advanced or Metastatic by Association Gemcitabine-Cisplatin

Clinical Trial Summary

The purpose of this study is to determine whether association Gemcitabine-Cisplatin is effective in the treatment of penis epidermoid carcinoma loco-regionally advanced or metastatic.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00210041
Study type Interventional
Source Institut Claudius Regaud
Contact
Status Completed
Phase Phase 2
Start date February 2004
Completion date December 2012
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03344757 - Health Gatherings - For Your Health After Cancer N/A
Terminated NCT02606123 - Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT01464216 - MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness
Terminated NCT04221828 - Trial of NanoPac Focal Therapy for Prostate Cancer Phase 2
Terminated NCT01918605 - Protection of Rectum From High Radiation Doses Using a Spacer N/A
Completed NCT01316458 - Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy Phase 2
Active, not recruiting NCT02266745 - A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Phase 2
Terminated NCT02499952 - Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors Phase 2
Active, not recruiting NCT04249947 - P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) Phase 1
Active, not recruiting NCT04461509 - High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy Phase 2
Active, not recruiting NCT05150236 - EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC Phase 2
Terminated NCT00672009 - A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer Phase 2
Approved for marketing NCT01217697 - Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer N/A